[{"orgOrder":0,"company":"Cambium Bio","sponsor":"Aventacell Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"CAM-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cambium Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cambium Bio \/ Aventacell Biomedical","highestDevelopmentStatusID":"8","companyTruncated":"Cambium Bio \/ Aventacell Biomedical"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant, Sustained Release","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant, Sustained Release","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The proceeds will primarily support the advancement of CAM-101 Elate Ocular through its registration-enabling Phase 3 clinical trials for dry eye disease.

                          Product Name : CAM-101

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 12, 2024

                          Lead Product(s) : CAM-101

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Aventacell Biomedical

                          Deal Size : $3.0 million

                          Deal Type : Financing

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : PA5108 Ocular Implant with Prezia™ technology are being developed to offer a safe and effective, fully biodegradable therapy, which is investigated for the treatment of Open-Angle Glaucoma .

                          Product Name : PA5108

                          Product Type : HPAPI

                          Upfront Cash : Inapplicable

                          February 17, 2022

                          Lead Product(s) : Latanoprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Opthea is working on a new drug that targets other VEGF proteins from those approved, including Bayer/Regeneron’s Eylea as well as Lucentis, namely VEGF-C and VEGF-D, for use in combination with VEGF-A drugs.

                          Product Name : OPT-302

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          September 25, 2020

                          Lead Product(s) : Sozinibercept,Ranibizumab

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $150.0 million

                          Deal Type : Public Offering

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The outcome of the meetings supports the progression of OPT-302 into Phase 3 and pre-commercial development. The company is on-track to initiate Phase 3 trials in early 2021.

                          Product Name : OPT-302

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 21, 2020

                          Lead Product(s) : Sozinibercept,Ranibizumab

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank